Drug intelligence / Profile preview

hICOSL-19

Development stage: Preclinical
Modality: Peptides

Overview

hICOSL-19 is a 19-residue peptide designed based on the human inducible co-stimulator ligand (ICOSL) structure. It functions as an antagonist of activated αVβ3 integrin through its arginine-glycine-aspartic acid (RGD)-motif. This peptide has demonstrated efficacy in mitigating proteinuria and reducing glomerular damage in mouse models of nephrotoxic serum (NTS)-glomerulonephritis and diabetic nephropathy. It is being investigated as a potential therapeutic option for glomerular diseases associated with αVβ3 activation, such as focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN).

Targets

αVβ3 (Integrin αVβ3)

Beyond the preview

Go deeper on hICOSL-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hICOSL-19.

Explore the full profile